Happy Stock Photo / shutterstock.com
Japanese pharmaceutical company Astellas and German biopharmaceutical company Ganymed have entered into an agreement under which Astellas will acquire Ganymed for €422 million ($462 million).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Astellas, Ganymed, mergers & acquisition, Xtandi, cancer drugs